A validate and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA neutralising antibodies for vaccine development and comparison.

ABSTRACT: Background: Over the past few decades, WHO has made massive efforts to promote the development of a vaccine against Lassa virus (LASV), one of the top ten priority pathogens for research and development under the WHO R&D Blueprint for Emerging Infections. To date, several vaccines are at different stages of development. In this scenario, a validated and standardised assay to measure LSV neutralising antibodies is urgently needed for vaccine development and comparison. Methods: The neutralisation assay remains the gold standard for determining antibody efficacy. Here we have proposed a safe and validated pseudotyped neutralisation assay for LASV, taking advantage of the development of the first WHO International Standard and Reference Panel for Anti-Lassa Fever (NIBSC code 21/332). Result

ORGANISM(S): Homo sapiens (human)

SUBMITTER:  

PROVIDER: S-BSST1413 | biostudies-other |

REPOSITORIES: biostudies-other